Learning Objective: Identify the overall risk of arthritis among children with psoriasis and subsequent risk of inflammatory comorbidities.
Introduction
Psoriatic arthritis (PsA) is one of 7 categories of juvenile idiopathic arthritis (JIA) as defined by the International League of Associations for Rheumatology (ILAR). Juvenile PsA is clinically diverse in its presentation and is diagnosed according to the ILAR criteria when a child presents with arthritis and psoriasis (PsO) or with arthritis plus at least 2 of the following: family history of PsO in a first-degree relative, dactylitis, or nail pitting. Studies have found that PsO, a major criterion for diagnosing PsA, affects 0% to 1.4% of children globally, 1,2 but relatively little is known about the epidemiology of pediatric PsA, including risk factors for the development of PsA among children with PsO. In one population-based study of 440 children with JIA, the presence of PsO or a PsO -like rash with at least 2 of the following variables significantly decreased the odds of attaining remission after 8 years: dactylitis, nail pitting, enthesitis, or first-degree relative with PsO or PsA. 3 Additionally, in comparison to other categories of JIA, with the exception of systemic JIA, children with PsA have a greater risk of disease flare after attaining inactive disease and stopping treatment. 4 There remains a critical need to better characterize the disease course and treatment of children with PsA, including description of the overall risk of arthritis in children with PsO and the time period during which patients with PsO are most at risk of developing arthritis.
Not all children or adults with PsO develop PsA. In adults, severity of PsO, smoking, obesity, hypercholesterolemia, trauma, uveitis, and depression have been identified as clinical risk factors in the development of PsA. 2, [5] [6] [7] [8] [9] [10] These triggers may stimulate an inflammatory cascade, ultimately leading to arthritis, enthesitis, and dactylitis. Studies have not yet examined risk factors for the development of arthritis in children with PsO.
After diagnosis of PsA, there is also an increased risk of cardiometabolic comorbidities in comparison to the general population without PsA. In a population-based study, adults with PsA had increased incidence rates of Crohn disease, uveitis, osteoporosis, and fibromyalgia compared to patients with PsO without arthritis. 11 In another United Kingdom population-based cohort study, patients with PsA had an increased risk of uveitis and Crohn disease when compared to the general population and PsO controls. 12 Incidence of these clinically relevant comorbidities has not been evaluated in the pediatric PsA population. In this population-based pediatric study, we aimed to identify the overall risk of arthritis and clinical features associated with the development of arthritis among children with PsO and subsequent risk of inflammatory comorbidities.
Methods

Study Design
Retrospective population-based cohort study.
Data Source
Clinformatics Data Mart (OptumInsight, Eden Prairie, Minnesota) is an administrative deidentified claims database derived from a large national commercial health insurance and Medicare Advantage (C and D) database. It contains deidentified data on approximately 64 million unique patients, representing approximately 20% of US residents. Available data include demographics, prescription drug claims, medical diagnoses specified by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, procedure codes, and provider specialty.
Participants
The source population for this study was children diagnosed with PsO or PsA between May 1, 2000, and June 30, 2013 (N ¼ 26 710) who were 0 to 16 years old at the time of diagnosis. To ensure that the cohort represented children with an incident code of PsO or PsA, any participants with a code for PsO or arthritis within the first 12 months of enrollment in the database were excluded. For the analysis, children with incident PsO were defined as children with at least 2 ICD-9-CM codes indicating PsO separated by a minimum of 7 days but no more than 183 days during the enrollment period. The first code for PsO was considered the index date for PsO. Children with PsA were identified by one of 4 algorithms: (1) at least 2 ICD-9-CM codes indicating PsA (696.0) separated by a minimum of 7 days but no more than 183 days 13, 14 ; (2) .00-720.02, 720.8, and 720.9); (4) 2 codes indicating PsO plus 1 code indicating arthritis and at least one of the qualifying criterion from algorithm 2. Approximately 50 records of those excluded were manually reviewed to search for possible errors or missed codes to confirm the diagnosis, and none were identified. Children from the source population without PsA or PsO were matched on age and sex at a 10:1 ratio to patients with PsO and PsA. The index date was identified as the date of first ICD-9-CM code for arthritis for patients with PsA, first ICD-9-CM code for PsO for the PsO only group, and match date for controls. Only enrollment periods with continuous coverage were used for outcome diagnoses (arthritis and PsO). Additional periods of enrollment were included if the gap in coverage did not exceed 90 days. These expanded enrollments were used to capture comorbid conditions (inflammatory bowel disease [IBD], uveitis, diabetes, hypertension, hyperlipidemia, and depressive disorder) not expected to be impacted by a gap in coverage.
Statistical Analysis
Clinical and demographic characteristics were summarized by mean and standard deviation or median and interquartile range (IQR) for continuous variables and count and percentage for categorical variables. Univariate Cox proportional hazard regression analysis was performed to identify risk factors for the development of arthritis in children with PsO. Variables with a P value < .20 in univariate analysis were considered in multiple regression analysis. Incidence rate ratios (IRRs) were computed to evaluate the relative frequency of comorbid diagnoses of IBD, uveitis, diabetes, hypertension, hyperlipidemia, and depressive disorder in children with PsO with and without arthritis and in controls.
Humans Protections
The protocol for this study was reviewed and approved by the Children's Hospital of Philadelphia Committee for the Protection of Human Subjects (IRB : 14-011409). Waivers of consent and assent were granted for this retrospective study of deidentified data.
Results
During the study period, 25 346 children had at least 1 code for PsO. One thousand three hundred twenty-seven children had at least one code for PsA or PsO plus at least one code indicating juvenile arthritis. Restricting the cohort to patients with incident diagnoses (clean period of 365 days) reduced the eligible study population to 14 612 patients with PsO and 714 patients with PsA. Of this source population, only 4312 children met inclusion criteria for the PsO cohort and 212 met inclusion criteria for PsA. The median time for continuous enrollment in the database was 63.9 months (IQR: 41.5-93.3). Patients who had a single code for PsA or arthritis but did not meet the more stringent inclusion criteria for PsA (n ¼ 400) were most commonly seen by providers in the following specialties: dermatology (n ¼ 136; 34.0%), orthopedics (n ¼ 85; 21.3%), family practice/pediatrics (n ¼ 84; 21.0%), rheumatology (n ¼ 39; 9.8%), general acute care hospital (n ¼ 14; 3.5%), emergency care/emergency medicine (n ¼ 12; 3.0%), and ophthalmology (n ¼ 10; 2.5%). The remainder of the cases came from providers in specialties not included in the above categories (n ¼ 20; 5.0%).
The overall prevalence of arthritis in children with PsO was approximately 2%. Of the 212 children with PsA, 44% never had a documented code indicating PsO. Of the 93 children with diagnosis codes meeting our inclusion criteria for both PsO and arthritis, the index date for arthritis preceded the index date for PsO in 22 (23.7%) children. For the 70 (33.0%) patients who developed PsO first, the median time to development of arthritis was 17.6 months (IQR: 4.1-38.1). The median time to development of PsO in patients who had arthritis first was 5.4 months (IQR: 1.4-13.5). Demographics of children with PsO and PsA are presented in Table 1 .
Clinical Features Associated With Development of Arthritis in Children With PsO
Results of univariate and multiple regression modeling of clinical features associated with development of arthritis in children with PsO are presented in Table 2 .
In multivariate analysis, age at PsO index date and preceding diagnosis of uveitis were significantly associated with a diagnostic code of arthritis in children who had PsO (P < .01).
Disease-Related Comorbidities
The incidence of disease-related comorbidities is presented in 
Discussion
This is the first study to examine risk factors for the development of arthritis in children with PsO and subsequent risk of comorbid diagnoses in a population-based cohort. We found that 44% of children with PsA had at least 1 code for PsO and only 2% of children with PsO received a code for arthritis within the follow-up period (5.25 years on average). The demographics of this cohort, other than a slightly older age of diagnosis, are consistent with prior reports. 15, 16 Uveitis and older age at the time of first PsO code were associated with a significantly increased risk of developing arthritis in children with PsO. Children with PsA had a significantly increased risk of clinically important comorbidities, including IBD, uveitis, diabetes, and depressive disorder, when compared to controls. Patients with PsA also had a greater risk of developing uveitis, diabetes, and depressive disorder when compared to children with PsO without arthritis. We also found patients with PsO without arthritis had a higher risk of hyperlipidemia than controls, which is in line with the results from Tollefson et al. 17 However, we were unable to find statistically significant increased risk of diabetes or hypertension children with PsO compared to controls, likely due to the differences in inclusion criteria and sample sizes between the studies.
In this study, we found that children with PsO or PsA had a significantly increased risk of developing IBD. Limited data exist on the connection between IBD and PsO or PsA in children. Most literature to date focuses on the development of PsO secondary to treatment with antitumor necrosis factor a agents. [18] [19] [20] We demonstrated that the risk of IBD was higher in children with PsA than in patients with PsO and no arthritis. This finding is concordant with recent work from the Netherlands that demonstrated that risk of IBD was higher in adults with PsA than in adults with PsO and no arthritis. 21 Genome-wide association studies have shown shared susceptibility loci in patients with PsO and IBD, 22 so these associations are not surprising. This, however, is the first study to demonstrate these associations in pediatric-onset disease. These findings have important implications for clinical care. While many pediatric rheumatologists maintain a high index of suspicion for concomitant IBD in children with enthesitis-related arthritis, the same is not necessarily the case for children with PsA. Abbreviations: CI, confidence interval; IBD, inflammatory bowel disease; IR, incidence rates; IRR, incidence rate ratios; PsA, psoriatic arthritis; PsO, psoriasis.
We aimed to identify a robust cohort of patients with PsO and PsA. As such, documentation of a single ICD-9-CM code for PsO or PsA was not considered sufficient for inclusion in the analytic cohort; the requirement for at least 2 diagnostic codes is consistent with prior well-performing validated algorithms in other administrative 23, 24 and integrated health-care databases. 25 Applying these algorithms to our cohort, we felt that excluding patients who technically did not meet ILAR criteria for PsA due to the exclusionary criteria (ie, acute anterior uveitis, IBD) was not necessary because we feel our algorithms capture cases that represent the clinical nature and pathogenesis of PsA. Restricting to patients with at least 2 diagnostic codes for PsA or 1 diagnostic code plus a medication used to treat PsA ensured physicians were diagnosing and treating their patients as if they had PsA. Other patients had at least 2 codes for arthritis and PsO, the major criteria for diagnosis of PsA. One study comparing the Vancouver criteria 26 to the ILAR criteria found that within a cohort of 139 patients meeting the Vancouver criteria for PsA, statistical analysis found almost no clinical differences between the group who met ILAR criteria versus those who did not. 27 The majority of patients who were excluded under ILAR (76%) were reclassified as another subtype of JIA but were phenotypically similar to the patients included under ILAR criteria for PsA. 27 The adult classification system for PsA, Classification Criteria for Psoriatic Arthritis (CASPAR), 28 does not employ any exclusionary criteria. Applying CASPAR to a JIA cohort of 6043 patients within the Childhood Arthritis and Rheumatolgy Research Alliance legacy registry identified 52 patients who were classified as some JIA subtype other than juvenile PsA that would have been diagnosed as PsA by an adult rheumatologist. 16 These patients exhibited less PsO but more enthesitis, IBD, uveitis, and inflammatory back pain, 16 all characteristics of the clinically similar umbrella of spondyloarthritis that can begin as juvenile disease and carry into adulthood. 29 Classification Criteria for Psoriatic Arthritis has been suggested as a potential diagnostic tool for use in defining juvenile PsA that could improve the transition from pediatric to adult care teams. 16 Surprisingly, even though we used 4 different algorithms to identify children with PsA that included not only diagnostic codes but also procedure and medication codes, only 19% of those with 1 code for PsA (or 1 code for juvenile arthritis in the background of PsO) met our more stringent inclusion criteria. The vast majority (90%) of single codes for PsA or arthritis were made by providers who do not typically diagnose or treat arthritis. The presence of only a single code for arthritis could mean one of the following: (1) providers are using the code(s) for PsA or arthritis in children with PsO nonspecifically, perhaps for arthralgia but not "true" arthritis (including as "ruleout" codes when a patient is in the process of being evaluated for possible arthritis), (2) children with PsO are being diagnosed with arthritis and not receiving further diagnostic evaluation or longitudinal care for the arthritis, (3) arthritis is occurring with reasonably high prevalence but resolves in the majority of the cases, perhaps due to systemic therapy that patients are receiving for PsO, or (4) providers are only coding the diagnosis at first encounter and not at subsequent visits. Unfortunately, due to the administrative nature of the data, we cannot obtain clinical information to further examine the reason for the presence of a single code. Of the possibilities, the second is most concerning as longitudinal care for children with PsA is not only important to preserve joint integrity and function but also to monitor for and treat uveitis, which can be vision threatening.
One of the strengths of this study is the large patient population that includes a broadly representative group of children across the United States. It is important, however, to interpret our study in light of potential limitations. First, this study was conducted utilizing a large retrospective administrative database. As such, we are limited to assessment of diagnoses and symptoms that can be coded. In particular, this may result in an underestimation of the prevalence and incidence of arthritis in children with PsO. Second, the duration of continuous enrollment was limited to under 6 years for the majority of patients. Therefore, detection of arthritis in children with PsO and comorbidities after diagnosis was limited to a relatively short period of time, likely leading to underestimation of the prevalence of comorbidities and biasing our results toward the null. However, the fact that there were still significant findings suggests that these associations are even stronger than we are able to demonstrate with this data. Third, as with any administrative database, there is risk of misclassification given the use of diagnostic codes. The diagnosis of PsA in children is challenging; children with PsO may be coded as PsA or nonspecific arthritis. In order to address this concern for misclassification, we examined several algorithms for identifying PsA. This is the first study to assess risk factors associated with the development of arthritis in children with PsO and the first to demonstrate that this group of children is at increased risk for IBD and other clinically important comorbidities including uveitis, diabetes, and depressive disorder. Additional studies are needed to identify the mechanisms underlying these associations and the impact on long-term outcomes into adulthood.
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